Galectin Therapeutics Inc. filings document a clinical-stage biotechnology issuer developing galectin-targeted therapeutics, including belapectin for MASH cirrhosis and portal hypertension. Form 8-K reports furnish operating results, financial condition updates, business updates, Regulation FD materials, and clinical-program disclosures tied to NAVIGATE trial presentations and corporate presentations.
The company’s proxy and governance filings cover director elections, advisory votes on executive compensation, auditor ratification, board changes, officer compensation arrangements, and annual meeting results. Its SEC records also identify GALT common stock registered on The Nasdaq Stock Market and include risk-factor references related to forward-looking clinical development and financing needs.
Galectin Therapeutics Inc. director Elissa J. Schwartz received a grant of stock options for 60,000 shares of common stock. The options were awarded on January 16, 2026 under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and an expiration date of January 16, 2036.
The filing states that these options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Schwartz beneficially owns 60,000 derivative securities in the form of stock options, held directly.
Galectin Therapeutics director and 10% owner Richard E. Uihlein reported equity awards from the company. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share under the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. These options vest 100% on December 31, 2026.
On the same date, he was also issued 13,158 shares of common stock at $3.04 per share in lieu of a $40,000 cash retainer and meeting fees for 2026, with restrictions on these shares lapsing 25% at the end of each calendar quarter in 2026. Following these transactions, he directly held 10,332,676 common shares and 60,000 options, and indirectly 27,710 shares through the Ed Uihlein Family Foundation, where he shares voting and dispositive power but has no pecuniary interest.
Galectin Therapeutics Inc. President and CEO Joel Lewis, who also serves as a director, reported equity compensation activity involving the company’s common stock. On January 5, 2026, 56,332 shares of common stock were reported at a price of $3.88 per share, reflecting settlement of deferred stock units (DSUs) and related share withholding for taxes. Following the transaction, Lewis beneficially owned 776,260 shares directly, which represent shares underlying DSUs and common stock.
Under Lewis’s employment and Deferred Stock Unit Agreements, 80% of his compensation is paid in DSUs, with DSUs from the amended agreement settling in common stock, including a tranche on January 5, 2026. The filing also shows 2,000 shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which Lewis expressly disclaims beneficial ownership.
Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026. The company states that his resignation is not due to any disagreement with Galectin on its operations, policies, or practices, indicating an orderly governance change rather than a dispute-driven departure.
Galectin Therapeutics Inc. President and CEO Joel Lewis reported several equity transactions in company stock. On January 2, 2026, 84,000 shares of common stock were acquired at $0 per share upon vesting of Restricted Stock Units, and on the same day 18,571 shares were sold at a weighted average price of $4.1968 per share under a pre-arranged Rule 10b5-1 trading plan. Additional sales of 27,731 shares at a weighted average price of $3.9069 on January 5, 2026 and 37,698 shares at a weighted average price of $3.5772 on January 6, 2026 were also reported.
Following these transactions, Lewis directly beneficially owned 832,592 shares of Galectin Therapeutics common stock. The filing also notes 2,000 shares held in an account where he acts as custodian for a minor child under the Uniform Transfers to Minors Act, for which he disclaims beneficial ownership. The transactions involving multiple sale prices are reported using weighted average prices, with detailed breakdowns available on request.
Galectin Therapeutics Chief Financial Officer Jack W. Callicutt reported a series of equity transactions in early January 2026. On January 1, 2026, 60,000 Restricted Stock Units converted into common shares at an exercise price of $0, and on January 2, 2026 he acquired 60,000 common shares for no additional consideration upon vesting.
Also on January 2, 2026, he sold 13,914 common shares at a weighted average price of $4.1968, followed by sales of 25,732 shares on January 5, 2026 at a weighted average of $3.8978 and 20,354 shares on January 6, 2026 at a weighted average of $3.6698. These sales, totaling 60,000 shares, were made under a Rule 10b5-1 trading plan adopted on April 17, 2025, and left him holding 7,614 common shares directly.
Galectin Therapeutics Inc Chief Medical Officer Jamil Khurram reported vesting and sales of company common stock. On January 2, 2026, 60,000 shares of common stock were acquired at $0 upon vesting of previously granted restricted stock units, then 13,055 of those shares were sold at a weighted average price of $4.1968. Additional sales of 25,499 shares at a weighted average price of $3.8985 on January 5, 2026, and 21,446 shares at a weighted average price of $3.6466 on January 6, 2026, reduced his reported holdings to zero shares. The filing notes that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025.
GALT shareholder Harold Shlevin filed a notice to sell up to 441,500 common shares, with an aggregate market value of 1,836,640, through Merrill Lynch on NASQ around 01/02/2026. The filing lists 64,472,792 common shares outstanding for the issuer. The planned sale shares were acquired via a 6,500-share open market purchase on 12/30/2024 and multiple stock option exercises between 2018 and 2024, including 60,000 shares on 01/23/2025. In the prior three months, Shlevin sold 159,000, 16,790, 19,793, 8,417 and 24,706 common shares in December 2025, with gross proceeds ranging from 52,541.90 to 943,448.33.
Galectin Therapeutics Inc. director and more than 10% owner associated with 10X Fund, L.P. reported recent changes in holdings. On 11/24/2025, 24,000 shares of common stock were transferred in an in-kind distribution to a withdrawing limited partner of 10X Fund, L.P., with no consideration received, which is described as exempt from short-swing profit rules. On 12/16/2025, 30,681 common shares were sold in multiple transactions at a weighted average price of $6.66 per share, with individual trade prices ranging from $6.64 to $6.69. After these transactions, the reporting entities show beneficial ownership of 5,614,457 Galectin Therapeutics shares held directly by 10X Fund, L.P., with 10X Capital Management, LLC and James C. Czirr reporting potential indirect ownership through their roles.
Galectin Therapeutics director Jack W. Callicutt reported option exercises and related stock sales under a Rule 10b5-1 trading plan adopted on August 29, 2025. On December 12, 2025, he exercised stock options to acquire 19,793 common shares at an exercise price of $4.16 and sold 19,793 shares at a weighted average price of $6.274, leaving 11,206 shares held directly.
On December 15, 2025, he exercised options to acquire 8,417 shares at $4.16 and sold 8,417 shares at a weighted average price of $6.3, with 11,206 Galectin Therapeutics shares shown as beneficially owned directly after the reported transactions. The options exercised have a $4.16 exercise price, vested 25% on June 30, 2018, 25% on September 30, 2018, and 50% on December 31, 2018, and expire on May 22, 2028.